Crossmark Global Holdings, Inc. Xencor Inc Transaction History

Crossmark Global Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$26.68 - $41.63 $167,550 - $261,436	-6,280 Closed	0 $0
Q4 2021 Jan 10, 2022	SELL	$33.67 - $43.44 $232,323 - $299,736	-6,900 Reduced 52.35%	6,280 $252,000
Q3 2021 Oct 21, 2021	BUY	$30.65 - $35.68 $403,967 - $470,262	13,180 New	13,180 $430,000
Q3 2021 Oct 13, 2021	SELL	$30.65 - $35.68 $404,273 - $470,619	-13,190 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$34.33 - $44.68 $3,089 - $4,021	90 Added 0.69%	13,190 $455,000
Q1 2021 Apr 15, 2021	BUY	$40.81 - $53.88 $15,915 - $21,013	390 Added 3.07%	13,100 $564,000
Q4 2020 Jan 14, 2021	BUY	$36.63 - $47.63 $271,428 - $352,938	7,410 Added 139.81%	12,710 $555,000
Q3 2020 Oct 08, 2020	BUY	$30.09 - $43.02 $159,477 - $228,006	5,300 New	5,300 $206,000
Q4 2019 Feb 06, 2020	SELL	$32.75 - $41.43 $391,690 - $495,502	-11,960 Closed	0 $0
Q3 2019 Oct 09, 2019	BUY	$33.73 - $46.27 $403,410 - $553,389	11,960 New	11,960 $403,000

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.